SAR-421869

N/A

Report date: 2026/01/20 17:48:46

Base Information

Drug NameSAR-421869
Drug Alias NameMY07A gene therapyMyosin VIIA gene therapyUsher syndrome gene therapyUshStatSAR-421869
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionGene transferenceCardiac myosin stimulants
TargetsCardiac myosin
Therapy Area/IndicationsRetinitis PigmentosaUsher Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOxford Biomedica
China Registration ClassN/A

Develop Information

Active CompaniesSanofi
Inactive CompaniesN/A
Active IndicationsUsher Syndromes
Inactive IndicationsRetinitis Pigmentosa

Other Information

ATC CodeN/A
Related LinksN/A